SecureTech Backing Enables AI UltraProd’s U.S. Accessory Dwelling Unit Beachhead; 2026 Rollout and Expansion Strategy Roseville, Minnesota, Dec. 08, 2025 (GLOBE NEWSWIRE) — AI UltraProd, Inc. (“Ai UltraProd”, AIUP”, or “the Company”), a global leader in AI-driven industrial solutions specializing in robotic 3D printing and advanced intelligent manufacturing systems, and a wholly owned subsidiary of SecureTech Innovations, Inc. (“SecureTech”) (OTCQB: SCTH), today announced its official entry into the United States market, beginning with a focused strategy centered on the rapidly expanding Accessory Dwelling Unit (ADU) sector. The decision follows extensive market analysis, emerging regulatory alignment, and growing nationwide demand for faster, more sustainable, and more affordable residential construction...

STEINHAUSEN, Switzerland, Dec. 08, 2025 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced the execution of a six-well contract in Australia with an undisclosed operator for the Deepwater Skyros. The estimated 320-day campaign is expected to commence in the first quarter of 2027 and contribute approximately $130 million in backlog, excluding compensation for mobilization and demobilization. The award includes priced options that, if fully exercised, could keep the drillship working in Australia into early 2030. About Transocean Transocean is a leading international provider of offshore contract drilling services for oil and gas wells. The company specializes in technically demanding sectors of the global offshore drilling business with a particular focus on ultra-deepwater and harsh environment drilling...

HERZLIYA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) — Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) (the “Company”) announced today, further to its announcement of December 7, 2025, that the Company completed in Israel a tender to qualified investors as defined under the Israeli Securities Law, 1968 (“Qualified Investors”) of notes, by expanding its Series A Notes, and Series 1 Warrants (the “Notes” and the “Warrants”, respectively and together, the “Securities”). General The Securities were offered to Qualified Investors in units, with each unit consisting of NIS 1,000 principal amount of Notes and three Warrants, with each such warrant exercisable into one ordinary share of the Company (the “Unit”). The Securities were offered by way of expansion of the Company’s existing Series A Notes and Series 1 Warrants, which were first listed for...

Lunsumio in combination with lenalidomide may offer an effective treatment in relapsed or refractory follicular lymphoma based on first data from single-arm US cohort of phase III CELESTIMO study1 Data from subcutaneous Lunsumio plus Polivy reinforce its outpatient, chemotherapy-free potential in people with R/R large B-cell lymphoma2,3 Results highlight the potential of innovative Lunsumio combination regimens to offer improved outcomes for more people with lymphoma earlier in their diseaseBasel, 8 December 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different types of lymphoma, presented at the 67th American Society of Hematology Annual Meeting and Exposition, 6-9 December 2025 in Orlando, Florida,...

Media Release COPENHAGEN, Denmark; December 8, 2025Two-year epcoritamab monotherapy data demonstrate high complete response and encouraging survival rates in patients with Richter transformation (RT), highlighting its potential as a treatment option for those unsuitable for chemotherapy Additional early data show promising efficacy of epcoritamab combination regimens in patients with RT Results underscore the potential of epcoritamab as a versatile therapy for a broad range of B-cell malignanciesGenmab A/S (Nasdaq: GMAB) today announced new and updated data from three arms of the ongoing Phase 1b/2 EPCORE® CLL-1 trial (NCT04623541) evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination for the treatment of patients with Richter...

GREENVILLE, S.C., Dec. 08, 2025 (GLOBE NEWSWIRE) — United Community Banks, Inc. (NYSE: UCB) (the “Company”) today announced that the Company’s Board of Directors approved a common stock repurchase program, authorizing the repurchase of up to $100.0 million of its outstanding common stock on the open market, in privately negotiated transactions, or in any other manner that complies with the provisions of the Securities Exchange Act of 1934, as amended (the “Stock Repurchase Program”). The Company may make repurchases under the Stock Repurchase Program from time to time beginning after the expiration of its current common stock repurchase program on December 31, 2025, and ending on December 31, 2026. The Company has repurchased $44 million of shares in 2025 under its current common stock repurchase program. The Stock Repurchase Program...

REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with propranolol and granulocyte colony-stimulating factor (G-CSF) for the mobilization of hematopoietic progenitor cells (HPCs) in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation (AHCT). The data, which showed that approximately 90% of study participants achieved the primary endpoint, were presented today in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. Burixafor is an investigational small molecule that blocks CXCL12 binding to CXCR4 receptors on HPCs,...

LONG BEACH, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced the Neutron launch vehicle’s innovative “Hungry Hippo” captive fairing has successfully completed qualification testing and is enroute to Virginia for Neutron’s first launch. Dubbed the Hungry Hippo, Neutron’s fairing halves remain attached to the rocket’s first stage throughout launch and landing back to Earth – a world-first for a reusable commercial rocket. Whereas typical rockets’ fairing halves fall away during launch and are disposable or require collection at sea for reuse, Neutron’s fairing halves open to release the rocket’s second stage and mission payload before closing again to return Neutron to Earth as a single reusable vehicle...